Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol

By sjmartinez • November 29, 2024

Newell-Price J, Fleseriu M, Pivonello R, Feelders RA, Gadelha MR, Lacroix A, Witek P, Heaney AP, Piacentini A, Pedroncelli AM, Biller BMK. Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol. J Endocr Soc. 2024 Nov 12;9(1):bvae201. doi: 10.1210/jendso/bvae201. PMID: 39610378; PMCID: PMC11604051.

Tags: cortisol normalization, Cushing disease, Endocrinology, hypercortisolism, long-term treatment, osilodrostat, Publications

FXYD2 marks and regulates maturity of (beta) cells via ion channel-mediated signal transduction

Tacto C, Tahbaz M, Salib A, Wang S, Cayabyab F, Choi J, Kim K, Hamba Y, Perez H, Gershon PD, Damoiseaux R, Oh TG, Yoshihara[...]

Determining Insulin Pump Candidacy: The Disconnect Between Clinical Care Guidelines and Clinical Practice

Everett E, Dao L, Munaganuru N, Udeze K, Gutierrez S, Gann S, Meda A, Tiu R, Arevalo A, Drexler C, Abdulrahman Y, Santana C, Moin[...]

mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage

Verdejo HE, Parra V, Del Campo A, Vasquez-Trincado C, Gatica D, Lopez-Crisosto C, Kuzmicic J, Venegas-Zamora L, Zuñiga-Cuevas U, Troncoso MF, Troncoso R, Rothermel BA,[...]